Shares of Sol-Gel Technologies SLGL moved higher by 0.1% after the company reported Q3 results.
Quarterly Results
Earnings per share increased 0.00% year over year to ($0.37), which beat the estimate of ($0.46).
Revenue of $2,116,000 decreased by 55.29% from the same period last year, which beat the estimate of $1,820,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Nov 12, 2020
Time: 07:05 AM
ET Webcast URL: https://www.sol-gel.com/
Technicals
Company's 52-week high was at $21.00
Company's 52-week low was at $5.00
Price action over last quarter: Up 15.90%
Company Description
Sol-Gel Technologies Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
